Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies

Alice Mannocci1, Emma De Feo1, Chiara de Waure1, Maria Lucia Specchia1, Maria Rosaria Gualano1, Carlo Barone2, Walter Ricciardi1, and Giuseppe La Torre3

1HTA Public Health Unit, Institute of Hygiene, and 2Clinical Oncology Unit, Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome; 3Clinical Medicine and Public Health Unit, Sapienza University of Rome, Italy

ABSTRACT

Aims and background. Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of ErbB, has determined clinical benefit for women affected by metastatic or early stage HER2-positive breast cancer and never previously treated with trastuzumab. Trastuzumab is generally used as first-line treatment of HER2+ metastatic breast cancer and is currently administered beyond progression even without clear evidence supporting such clinical practice. In fact, HER2-positive metastatic breast cancer has a high risk of progressing after first-line therapy, and second-line treatments vary. The aim of the study was to investigate by a systematic review the efficacy of trastuzumab-based treatments beyond progression in HER2-positive metastatic breast cancer.

Materials and methods. We performed a systematic review using Medline, Embase and Cochrane Library data bases and publications in principal meetings or congresses of oncology in Europe and America until September 2008. The main selection criterion was the reporting of time to progression, calculated from the start of each trastuzumab-based therapy to the date of progressive disease or death.

Results. Twelve studies were selected that included a total of 516 patients. The weighted mean time to progression was 23.66 weeks (standard deviation, 4.37) and the median was 26 weeks (range, 13-39). Interestingly, combined trastuzumab plus vinorelbine treatment showed a lower mean and median time to progression (20.59 and 19.57 weeks, respectively), whereas trastuzumab plus capecitabine yielded a mean time to progression of 30.33 weeks.

Conclusions. The added value of the present study has been to provide a quantitative summary measure of time to progression which can be used for comparisons between current and future available regimens. Free full text available at www.tumori-online.it

Key words: beyond progression, Herceptin, metastatic breast cancer, trastuzumab.

Correspondence to: Dr Alice Mannocci, Istituto di Igiene, Università Cattolica del Sacro Cuore, L.go Francesco Vito 1, 00168 Rome, Italy. Tel +39-06-35001525; fax +39-06-35001522; e-mail alice.mannocci@rm.unicatt.it

Received October 10, 2009; accepted January 13, 2010.